ETR:BAYN Bayer Aktiengesellschaft (BAYN) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free BAYN Stock Alerts €27.06 -0.28 (-1.02%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range€27.02▼€27.7250-Day Range€26.08▼€29.3852-Week Range€24.96▼€54.95Volume2.63 million shsAverage VolumeN/AMarket Capitalization$26.59 billionP/E RatioN/ADividend Yield0.41%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Bayer Aktiengesellschaft alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Bayer Aktiengesellschaft Stock (ETR:BAYN)Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.Read More BAYN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BAYN Stock News HeadlinesMay 29, 2024 | finanznachrichten.deFeier ohne Bayer - Aktie taucht (mal wieder) abMay 28, 2024 | finance.yahoo.comDavid Herro's Strategic Moves in Q1 2024 Highlight CNH Industrial NV's ImpactMay 28, 2024 | finanznachrichten.deBASF und Bayer: Bald wieder aufwärts?May 26, 2024 | finance.yahoo.comFurther weakness as Bayer (ETR:BAYN) drops 3.3% this week, taking one-year losses to 49%May 23, 2024 | bloomberg.comBayer Fights for Survival as Roundup Lawsuits Burn CashMay 23, 2024 | finance.yahoo.comBayer Sees ‘Existential’ Threat From Roundup Suits, CEO SaysMay 21, 2024 | finanznachrichten.deBayer Aktie: Analysten erwarten Aufwärtsbewegung beim AktienkursMay 20, 2024 | finanznachrichten.deTUI setzt auf seine App, Bayer kann mit der Werkself nicht mithalten, Nel ASA zittert und Siemens Energy gelobt Besserung!May 19, 2024 | finanznachrichten.deBayer: Jetzt gut aufpassen!May 17, 2024 | morningstar.comBayer AG Cedear BAYNMay 17, 2024 | finance.yahoo.comPharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline UpdatesMay 17, 2024 | finance.yahoo.comBayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory ApprovalMay 17, 2024 | finanznachrichten.deBayer: Studienerfolg für Mittel gegen Hitzewallungen in WechseljahrenMay 16, 2024 | finanznachrichten.deDie Zahlen von Bayer lagen leicht über den Erwartungen, doch auf die drängendsten Fragen der Aktionäre gibt es weiterhin keine AntwortMay 14, 2024 | markets.businessinsider.comWhat Wall Street expects from Bayer's earningsMay 14, 2024 | markets.businessinsider.comBayer is about to announce earnings — here's what Wall Street expectsMay 14, 2024 | finanznachrichten.deEvotec sorgt für neuen Mut, TUI vor dem Aufstieg, Nel ASA bleibt kampflustig und bei Bayer steigt die Spannung!May 14, 2024 | bizjournals.comBayer discloses 1,500 global job cuts in Q1; silent on Mass. impactMay 14, 2024 | finanznachrichten.deBayer nach den Zahlen: Kurs steigt auf 30 EuroMay 14, 2024 | markets.businessinsider.comBayer Q1 Profit Down; Confirms FY Currency-adj. ForecastMay 14, 2024 | msn.comBayer's first-quarter adjusted profit falls less than expectedMay 13, 2024 | finanznachrichten.deBayer Aktie: Spannung vor Veröffentlichung des QuartalsberichtsMay 12, 2024 | finanznachrichten.de1. Bundesliga: Bayer baut Serie auf 50 ungeschlagene Spiele ausMay 8, 2024 | finanznachrichten.deBei Evotec kehrt Ruhe ein, bei Nel ASA werden die Bullen immer mutiger, TUI weiterhin am Schwächeln und Bayer ist laut Analysten genug abgestraftMay 8, 2024 | finanznachrichten.deBayer vor Zahlen: Darauf können sich Anleger einstellenSee More Headlines Receive BAYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolETR:BAYN CUSIPN/A CIKN/A Webwww.bayer.com Phone49 214 30 1FaxN/AEmployees96,931Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€3.17) Trailing P/E RatioN/A Forward P/E Ratio5.18 P/E Growth36.39Net Income$-3,120,000,000.00 Net Margins-6.63% Pretax MarginN/A Return on Equity-8.13% Return on Assets4.04% Debt Debt-to-Equity Ratio129.38 Current Ratio1.31 Quick Ratio0.72 Sales & Book Value Annual Sales$47.01 billion Price / Sales0.57 Cash Flow€4.73 per share Price / Cash Flow5.73 Book Value€36.24 per share Price / Book0.75Miscellaneous Outstanding Shares982,420,000Free FloatN/AMarket Cap$26.59 billion OptionableNot Optionable Beta0.97 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. William N. Anderson (Age 58)Chairman of the Management Board & CEO Comp: $8.43MMr. Wolfgang U. Nickl (Age 55)CFO & Member of Management Board Comp: $1.98MMr. Heiko W. J. Schipper (Age 55)Member of Management Board & President of the Consumer Health Division Comp: $1.95MMr. Stefan Oelrich (Age 56)Head of the Pharmaceuticals Division & Member of the Board of Management Comp: $1.95MMr. Rodrigo Santos (Age 51)Member of Management Board & President of the Crop Science Division Comp: $2.17MMs. Heike Prinz (Age 60)Chief Talent Officer, Labor Director & Member of Management Board Comp: $1.33MMr. Julio Triana (Age 58)Member of Management Board & President of Consumer Health Division Dr. Sebastian Guth Ph.D.Chief Operating OfficerDr. Jost Reinhard (Age 52)Head of Investor Relations Mr. Michael PreussHead of Communications, Government Relations and Corporate BrandMore ExecutivesKey CompetitorsSanofiEPA:SANSiemens HealthineersETR:SHLMerck KGaAETR:MRKFresenius Medical CareETR:FMECarl Zeiss MeditecETR:AFXView All Competitors Should I Buy Bayer Aktiengesellschaft Stock? BAYN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Bayer Aktiengesellschaft: Bayer Aktiengesellschaft has shown resilience in its stock price, currently trading at an attractive valuation, making it a potential value investment opportunity. The company has a diverse product portfolio, including pharmaceuticals, consumer health, and crop science divisions, providing stability and potential for growth across different sectors. Bayer's recent focus on innovation and research & development has led to the introduction of cutting-edge products like the latest versions of its pharmaceuticals and crop protection solutions, enhancing its competitive edge in the market. The company's strong global presence and established brand reputation contribute to its ability to capture market share and expand into new markets, offering long-term growth prospects for investors. Bayer's commitment to sustainability and environmental responsibility aligns with the growing ESG (Environmental, Social, and Governance) investing trend, attracting socially conscious investors. Cons Investors should be bearish about investing in Bayer Aktiengesellschaft for these reasons: Bayer faces ongoing legal challenges and settlements related to its acquisition of Monsanto, which could lead to financial uncertainties and reputational risks for the company. The competitive landscape in the pharmaceutical and agricultural sectors is intense, with potential pricing pressures and regulatory hurdles that may impact Bayer's profitability and market position. Fluctuations in commodity prices and currency exchange rates can affect Bayer's earnings, especially in its crop science division, exposing investors to volatility in financial performance. Concerns about potential side effects or regulatory issues related to Bayer's pharmaceutical products could lead to market backlash and impact the company's revenue streams and stock performance. Global economic conditions and geopolitical factors may influence Bayer's operations and sales, posing risks to investors in terms of market uncertainties and macroeconomic challenges. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, June 6, 2024. Please send any questions or comments about these Bayer Aktiengesellschaft pros and cons to contact@marketbeat.com. BAYN Stock Analysis - Frequently Asked Questions How have BAYN shares performed in 2024? Bayer Aktiengesellschaft's stock was trading at €33.63 at the start of the year. Since then, BAYN stock has decreased by 19.5% and is now trading at €27.07. View the best growth stocks for 2024 here. Is Bayer Aktiengesellschaft a good dividend stock? Bayer Aktiengesellschaft (ETR:BAYN) pays an annual dividend of €0.11 per share and currently has a dividend yield of 0.40%. What other stocks do shareholders of Bayer Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bayer Aktiengesellschaft investors own include NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Lam Research (LRCX), QUALCOMM (QCOM), SAP (SAP), AbbVie (ABBV), Applied Materials (AMAT) and Advanced Micro Devices (AMD). This page (ETR:BAYN) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bayer Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Bayer Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.